Identification of Predictors for Early Cognitive Decline in Men

NCT ID: NCT03290040

Last Updated: 2023-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

564 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The research program explores how aging influences brain function in test-persons from a Danish birth cohort of men born in 1953.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The research program explores how ageing influences brain function in healthy test-persons from a Danish birth cohort of men born in 1953 in the Metropolitan area of Copenhagen. These test-persons are divided into two groups based on performance in cognitive tests at late midlife compared to young adulthood; Positive expected performance and negative expected performance and sampled from a birth cohort of 11.532 men.

Additionally, persons diagnosed with either MCI or AD will be included from the Memory Clinic at Herlev Hospital.

Researchers aim to identify factors earlier in life that affects or predict changes in cognitive function, specifically of cognitive decline in order to predict healthy vs unhealthy cognitive ageing, including progression to possible dementia. The objective is to be able to predict cognitive decline in ageing.

During the years of data collection, approximately 550 participants will be included and examined.

The examinations include:

* Cognitive test including Cambridge Neuropsychological test automated Battery (CANTAB);
* Sleep
* Life events
* Depression questionnaire
* Blood sample analysis including functional analyses of mitochondria and gene analyses such as genome scanning, SNP analysis
* ApoE ε-type
* Structural and functional changes in the brain measured with magnetic resonance (fMRI)
* Electroencephalography (EEG) recordings of electrical activity and visual attention
* PET-scan (Amyloid and FDG)

The results from these studies will hopefully point to new avenues for intervention in order to change the course of brain ageing

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Test Persons Mild Cognitive Impairment Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metropolit Cohort

Danish birth cohort of men born in 1953 in the Metropolitan area of Copenhagen. These test-persons are divided into two groups based on performance in cognitive tests at late midlife compared to young adulthood; Positive expected performance and negative expected performance and sampled from a birth cohort of 11.532 men.

No interventions assigned to this group

Herlev Hospital, Memory Clinic

Persons from the Memory Clinic at Herlev Hospital. These subjects are diagnosed with either MCI or AD.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who have participated in the Metropolit study and the Copenhagen Aging and Midlife Biobank project
* Participants who have been informed about the project and who have signed the informed consent form

Exclusion Criteria

* Persons who have been asked to participate in the past and have rejected
* Reduced ability to understand project information
* Reduced ability to complete the examinations
* Abuse of alcohol, psychedelic drugs or habit-forming drugs
* Certain neurological disorders
* Certain neurological, mental or psychiatric diagnoses
* Certain depressive diseases
* Former traumatic brain injury
* Contraindication for MR scanning
* Pathological MR result
* Persons that do not like to be informed about a possible pathological result
Minimum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Copenhagen

OTHER

Sponsor Role collaborator

Herlev Hospital

OTHER

Sponsor Role collaborator

Rigshospitalet, Denmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Martin Lauritzen

Professor, Consulting

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin J Lauritzen, Prof

Role: PRINCIPAL_INVESTIGATOR

Dept. of Clinical Neurophysiology, Rigshospitalet - Glostrup

Martin J Lauritzen, Prof

Role: PRINCIPAL_INVESTIGATOR

Dept. of Clinical Neurophysiology, Rigshospitalet - Glostrup, Neuronal Signalling Lab, Center for Neuroscience, and Center for Healthy aging, University of Copenhagen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept. of Clinical Neurophysiology, Department of Clinical Biochemistry and Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet - Glostrup

Glostrup Municipality, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-1-2014-032

Identifier Type: -

Identifier Source: org_study_id